Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study

Multiple sclerosis (MS) patients receiving natalizumab and who are at risk of developing progressive multifocal leukoencephalopathy (PML) often switch to other high-efficacy disease-modifying therapies including fingolimod as a risk mitigation strategy, which could impact treatment safety and effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Butzkueven, Helmut, Giacomini, Paul S., Cohan, Stanley, Ziemssen, Tjalf, Sienkiewicz, Daniel, Zhang, Ying, Geissbühler, Yvonne, Silva, Diego, Tomic, Davorka, Kropshofer, Harald, Trojano, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870332/
https://www.ncbi.nlm.nih.gov/pubmed/35203978
http://dx.doi.org/10.3390/brainsci12020215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870332/
https://www.ncbi.nlm.nih.gov/pubmed/35203978
http://dx.doi.org/10.3390/brainsci12020215

Ejemplares similares